Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas
Autor: | Panayiotis E. Pelargos, Seyed A. Hojat, Thien Nguyen, John P. Sheppard, Timothy F. Cloughesy, Lawrance K. Chung, Carlito Lagman, Linda M. Liau, Albert Lai, Robert M. Prins, Yu-Ling Chang, Joanna V. Demos, Isaac Yang, Ann M. Chan, William H. Yong, Lynn K. Gordon, Madhuri Wadehra, Leia Nghiemphu |
---|---|
Rok vydání: | 2018 |
Předmět: |
0301 basic medicine
Male Cancer Research Pathology Neurology Gene Expression 0302 clinical medicine Epithelial membrane protein-2 80 and over Molecular Targeted Therapy Cancer Aged 80 and over Tissue microarray Membrane Glycoproteins Tumor Brain Neoplasms Hazard ratio General Medicine Glioma Tissue Microarray Analysis Middle Aged Prognosis Immunohistochemistry Oncology 030220 oncology & carcinogenesis Biomarker (medicine) Female Adult medicine.medical_specialty Biology Article 03 medical and health sciences Rare Diseases Biomarkers Tumor medicine Humans Neoplasm Staging Aged Neurology & Neurosurgery Neurosciences Biomarker medicine.disease nervous system diseases Brain Disorders Brain Cancer 030104 developmental biology Ki-67 Antigen Membrane protein Tissue Array Analysis Neurology (clinical) Glioblastoma Biomarkers |
Zdroj: | Brain tumor pathology, vol 35, iss 1 |
Popis: | Epithelial membrane protein-2 (EMP2) expression is noted in many human cancers. We evaluated EMP2 as a biomarker in gliomas. A large tissue microarray of lower grade glioma (WHO grades II-III, n=19 patients) and glioblastoma (GBM) (WHO grade IV, n=50 patients) was stained for EMP2. EMP2 expression was dichotomized to low or high expression scores and correlated with clinical data. The mean EMP2 expression was 1.68 in lower grade gliomas versus 2.20 in GBMs (P=0.01). The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P=0.001). No significant difference was found between median survival among patients with GBM tumors exhibiting high EMP2 expression and survival of those with low EMP2 expression (8.38 vs. 10.98months, P=0.39). However, EMP2 expression ≥2 correlated with decreased survival (r=-0.39, P=0.001). The EMP2 expression level also correlated with Ki-67 positivity (r=0.34, P=0.008). The mortality hazard ratio for GBM patients with EMP2 score of 3 or higher was 1.92 (CI 0.69-5.30). Our findings suggest that elevated EMP2 expression is associated with GBM. With other biomarkers, EMP2 may have use as a molecular target for the diagnosis and treatment of gliomas. |
Databáze: | OpenAIRE |
Externí odkaz: |